Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?

Current treatment options in oncology - 1 Feb 2017

Cohen Romain, Cervera Pascale, Svrcek Magali, Pellat Anna, Dreyer Chantal, de Gramont Aimery, André Thierry

Abstract excerpt

OPINION STATEMENT: The BRAF activating mutation, harbored by approximately 10% of colorectal cancers (CRC), confers dramatic prognosis to advanced diseases. In early-stage setting, the identification of the BRAF mutation does not impact the therapeutic decision. Yet, the BRAF mutation could be considered as a stratification factor in adjuvant trials, because of its prognostic impact after relapse. Moreover, both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Microsatellite Instability

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 28214977
DOI: 10.1007/s11864-017-0453-5

Genes

BRAF
EGFR
MLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?PMID 28214977Read ↗

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.Semantic proximity Read ↗

BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable MutationSemantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

Molecular-Biology-Driven Treatment for Metastatic Colorectal CancerSemantic proximity Read ↗

BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.